A new implant to prevent HIV infection with less frequent dosing
Official title: A Bioresorbable Subdermal Implant for Sustained Delivery of a Novel Maturation Inhibitor to Prevent HIV Infection
Funded at Oak Crest Institute of Science · NIH-10892211 · Data updated 2026-11-12
This study is testing a new implant that slowly releases a special medicine to help prevent HIV, making it easier for people to stay protected without having to take a pill every day or month.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Oak Crest Institute of Science NIH-funded |
| Lab location | 1 site (Monrovia, United States) |
| Project start | August 28, 2020 |
| Project end | July 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $886,859 |
| NIH project number | 5R01AI154561-05 |
| Project ID | NIH-10892211 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals at high risk of HIV infection who may benefit from a long-acting prevention method.
✕Less likely to help
Patients who are already HIV positive or those who do not have risk factors for HIV infection may not receive benefit from this research.
What this research studies
This research focuses on developing a bioresorbable subdermal implant that delivers a novel drug to prevent HIV infection. The implant aims to improve adherence to HIV prevention methods by providing long-lasting protection without the need for daily or monthly dosing. The approach involves a detailed formulation development process, including design, fabrication, and testing in animal models to ensure safety and efficacy. Patients will benefit from a more convenient and effective method of HIV prevention.
Why it matters
Potential benefit: If successful, this research could provide a long-lasting and effective method for preventing HIV infection, reducing the burden of daily medication adherence.
How similar studies have gone: Other research has shown promise with long-acting drug delivery systems for HIV prevention, indicating potential for success with this novel approach.
Where this research is happening
-
Oak Crest Institute of Science
Monrovia, United States Active
Researchers
- Principal investigator: Moss, John a — Oak Crest Institute of Science
- Study coordinator: Moss, John a
Related research
Other NIH-funded projects on the same topics.
-
Understanding how genetic changes in blood cells relate to heart disease in people with HIV
A study will look at how age-related blood cell mutations and large chromosomal changes might contribute to heart disease risk in people living with HIV.
-
Cardiac health and protein markers in kids with perinatal HIV exposure or infection
A study from Duke aims to understand heart health and protein biomarkers in children who were exposed to or infected with HIV at birth, especially in sub-Saharan Africa.
-
HBV cure clues in people with and without HIV
This project studies how HBV-specific B and T cell responses relate to curing hepatitis B in people with and without HIV.
-
HBV cure factors in people with and without HIV
This project studies how HBV-specific immune cells behave during treatment and whether people with HIV respond differently than those without HIV.
-
Myocardial fibrosis and fat in ART-treated women with HIV in sub-Saharan Africa
This project studies heart tissue changes in women with HIV in sub-Saharan Africa who are on antiretroviral therapy, to understand why they’re at higher risk for heart problems as they age.
-
Myocardial fibrosis and fat in ART-treated women with HIV in sub-Saharan Africa
This grant studies heart tissue changes in women living with HIV in sub-Saharan Africa to understand why heart failure risk is higher in this group.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.